Cargando…

Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C

BACKGROUND: Patients with substance use disorders (SUD) and chronic hepatitis C virus infection (HCV) have limited access to direct-acting antivirals (DAAs) due to multilevel issues related to providers (eg, concern about reinfection); patients (eg, refusal); payers (eg, prior authorization); and he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Xinyi, Vouri, Scott Martin, Diaby, Vakaramoko, Lo-Ciganic, Weihsuan, Parker, Robert, Park, Haesuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968723/ https://www.ncbi.nlm.nih.gov/pubmed/34595949 http://dx.doi.org/10.18553/jmcp.2021.27.10.1388

Ejemplares similares

The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders
por: Jiang, Xinyi, et al.
Publicado: (2021)

Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection
por: Park, Haesuk, et al.
Publicado: (2022)

Trends, characteristics, race, and ethnicity associated with nonadherence to antidepressants among breast cancer survivors with depression
por: Chang, Ching-Yuan, et al.
Publicado: (2023)

Direct‐Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C
por: Park, Haesuk, et al.
Publicado: (2020)

Changes in Schedule II oral opioid volume dispensed in a private health plan following Florida’s Acute Pain Opioid Restriction Law
por: Oueini, Razanne, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
por: Tran, Phuong T., et al.
Publicado: (2020)

Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States
por: Park, Haesuk, et al.
Publicado: (2019)

Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada
por: Boulin, Mathieu, et al.
Publicado: (2016)

Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam
por: Due, Ong The, et al.
Publicado: (2020)

An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention
por: Okere, Arinze Nkemdirim, et al.
Publicado: (2018)

Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions
por: Diaby, Vakaramoko, et al.
Publicado: (2021)

Self-assessed life expectancy among older adults in Côte d’Ivoire
por: Moussa, Richard K., et al.
Publicado: (2020)

Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review
por: Xiao, Hong, et al.
Publicado: (2018)

Development and validation of a tool to predict high-need, high-cost patients hospitalised with ischaemic heart disease
por: Nkemdirim Okere, Arinze, et al.
Publicado: (2023)

Cost–utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China
por: Yun, Haoya, et al.
Publicado: (2020)

Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India
por: Aggarwal, Rakesh, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany
por: Runge, Melanie, et al.
Publicado: (2020)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population
por: Wang, Ching-Yu, et al.
Publicado: (2022)

The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries
por: Mennini, Francesco S., et al.
Publicado: (2021)

Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C
por: Lin, Sheng Feng, et al.
Publicado: (2020)

Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries
por: Jung, Jeah, et al.
Publicado: (2020)

Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan
por: Zhuo, Yueran, et al.
Publicado: (2020)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Cost–Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong
por: Yuen, Man-Fung, et al.
Publicado: (2020)

Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients
por: Al-Busafi, Said A., et al.
Publicado: (2017)

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
por: Barber, Melissa J., et al.
Publicado: (2020)

Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy
por: Girardin, François, et al.
Publicado: (2021)

Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid
por: Pham, Timothy T., et al.
Publicado: (2018)

Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism
por: Kang, Hye‐Rim, et al.
Publicado: (2023)

Value Assessment Frameworks in the United States: A Call for Patient Engagement
por: Diaby, Vakaramoko, et al.
Publicado: (2018)

Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study
por: Scott, Dr Nick, et al.
Publicado: (2021)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3anlef19i804oisg579n2l7jm5